ArticleAmerican journal of preventive cardiology2025
Temporal patterns of triglyceride testing and test results among adults with severe or extreme hypertriglyceridemia in US clinical practice.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep chemical structure graph learning deciphers the lipotoxicity code of hypertriglyceridemic pancreatitis.NPJ digital medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe hypertriglyceridemia (sHTG; triglyceride [TG] 500-879 mg/dL) and extreme hypertriglyceridemia (eHTG; TG ≥880 mg/dL), are risk-enhancing factors for atherosclerotic cardiovascular disease and acute pancreatitis, yet little is known about routine TG monitoring. This study characterized real-world frequency and patterns of TG testing and results among adults with sHTG/eHTG. Among 1.8 M adults, first observed TG was 500-879 for 0.7% and ≥880 for 0.2%. During mean follow-up of 27 months, 38% of patients with first TG 500-879 or ≥880 had one test, and among those with ≥2 tests, mean interval between first/second tests was ≥244 days. Among patients with first TG 500-879 and ≥3 tests, second TG was ≥500 for 26% and all three TGs were ≥500 for 11%. Among patients with first TG ≥880 and ≥3 tests, second TG was ≥500 for 46% and all three TGs were ≥500 for 30%. Findings suggest that follow-up TG testing is suboptimal, and TG results are persistently high for many patients with sHTG/eHTG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.